These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2444906)

  • 1. [Excess mineralocorticoid syndrome secondary to nasal sprays containing 9 alpha-fluoroprednisolone].
    Foresti V; Parisio E; Ricci G
    Minerva Med; 1987 Sep; 78(17):1305-11. PubMed ID: 2444906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hypokalemic myopathy in arterial hypertension].
    Santeusanio F; Nunzi E; Natali P; Nicoletti I; Angeletti G; Filipponi P; Rambotti P
    Minerva Med; 1982 Sep; 73(35):2279-86. PubMed ID: 7110606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid hypertension due to a nasal spray containing 9 alpha-fluoroprednisolone.
    Mantero F; Armanini D; Opocher G; Fallo F; Sampieri L; Cuspidi B; Ambrosi C; Faglia G
    Am J Med; 1981 Sep; 71(3):352-7. PubMed ID: 6169277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Exogenous hypermineralocorticism caused by a nasal spray containing 9-alpha fluoroprednisolone].
    Virgolini L; Geatti O; Giunta G
    Minerva Cardioangiol; 1984; 32(7-8):473-5. PubMed ID: 6208510
    [No Abstract]   [Full Text] [Related]  

  • 5. Factitious hypertension with mineralocorticoid excess in an infant.
    De Stefano P; Bongo IG; Borgna-Pignatti C; Severi F
    Helv Paediatr Acta; 1983 May; 38(2):185-9. PubMed ID: 6874387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The etiology of a syndrome of factitious mineralocorticoid excess: a steroid-containing nasal spray.
    Funder JW; Adam WR; Mantero F; Kraft N; Ulick S
    J Clin Endocrinol Metab; 1979 Dec; 49(6):842-6. PubMed ID: 92477
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hypokalemic myopathy caused by fluoroprednisolone in a nasal spray. Observations 2 cases].
    Cantello R; Bergamini L; Delsedime M; Durelli L; Troni W; Gilli M; Cocito D
    Minerva Med; 1983 Jun; 74(25):1463-7. PubMed ID: 6856155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypermineralcorticism syndrome secondary to topical application of 9-alpha-fluoroprednisolone (author's transl)].
    Vasconez F; Pérez-Garcia R; Olivas E; Bolívar JE; Valderrábano F
    Med Clin (Barc); 1980 Dec; 75(10):430-4. PubMed ID: 7464329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Arterial hypertension induced by an excess of mineralocorticoids caused by abuse of nasal spray. Report of a case].
    De Venuto G; Mattarei M; Dal Piaz A; De Santa A; Torboli PL; Miori R
    Minerva Med; 1984 Jun; 75(27):1673-77. PubMed ID: 6205328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An unusual cause of factitious mineralocorticoid excess.
    Vanderijst JF; Vandeleene B; De Plaen JF; Kolanowski J
    Acta Clin Belg; 1992; 47(6):408-13. PubMed ID: 1283935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exogenous mineralocorticoid-like disorders.
    Mantero F
    Clin Endocrinol Metab; 1981 Nov; 10(3):465-78. PubMed ID: 6178539
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe arterial hypertension caused by chronical abuse of a topical mineralocorticoid.
    Armbruster H; Vetter W; Reck G; Beckerhoff R; Siegenthaler W
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):170-3. PubMed ID: 51837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Severe hypopotassemia and rhabdomyolysis in a normotensive subject after use of a nasal spray containing 9-alpha-fluoroprednisolone].
    Wu SC; Secchi MB; Mancarella S; Oltrona L; Bettazzi L; Sale M; Ambrosi B
    Recenti Prog Med; 1989 Apr; 80(4):195-6. PubMed ID: 2762657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypopotassemia and rhabdomyolysis. Description of 3 cases of different etiologies].
    Maresca MC; Calconi G; Amici GP; Teodori T; Da Porto A
    Minerva Med; 1988 Jan; 79(1):55-60. PubMed ID: 3340316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypokalemic myopathy in pseudohyperaldosteronism induced by fluoroprednisolone-containing nasal spray.
    Vita G; Bartolone S; Santoro M; Toscano A; Carrozza G; Girlanda P; Frisina N
    Clin Neuropathol; 1987; 6(2):80-5. PubMed ID: 3594977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudoprimary aldosteronism from the topical application of 9-alpha-fluorprednisolone to the skin.
    Montoliu J; Botey A; Trilla A; Revert L
    Clin Nephrol; 1984 Nov; 22(5):262-6. PubMed ID: 6394185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normokalemic hyperaldosteronism in patients with resistant hypertension.
    Benchetrit S; Bernheim J; Podjarny E
    Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid hypertension and hypokalemia.
    Khosla N; Hogan D
    Semin Nephrol; 2006 Nov; 26(6):434-40. PubMed ID: 17275580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone and other mineralocorticoids in Bartter's syndrome.
    Saruta T; Fujimaki M; Senba S; Saito I; Konishi K
    J Lab Clin Med; 1984 Jun; 103(6):848-53. PubMed ID: 6373989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rhabdomyolysis, oedema and arterial hypertension: different syndromes related to topical use of 9-alpha-fluoroprednisolone.
    Lauzurica R; Bonal J; Bonet J; Romero R; Teixido J; Serra A; Caralps A
    J Hum Hypertens; 1988 Oct; 2(3):183-6. PubMed ID: 3236321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.